Literature DB >> 20517234

[D2 lymphadenectomy for surgical and combined treatment of the gastric cancer].

V Iu Skoropad, B A Berdov.   

Abstract

Immediate results of 100 D2 lymphadenectomies, performed for gastric cancer, were analyzed. The combined treatment included preoperative radiotherapy (n=39), combinations of pre- and postoperative radiotherapy (n=18) and adjuvant chemotherapy (n=18). The majority of patients had tumors of the lower third of the stomach, histologically low- and non-differentiated adenocarcinomas. Gastrectomy was performed in majority of cases. Achieved results showed, that pre- and postoperative radiotherapy led neither to lethality nor to complication rate or to hospital stay time increase. Thus, D2 lymphadenectomy for surgical and combined treatment of the gastric cancer, is a safe procedure with an acceptable rate of postoperative complications. It does not prevent neo- and adjuvant chemo- or radiotherapy conduction. D2 lymphadenectomy allows a more thorough cancer staging, according both to international and Japanese classifications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20517234

Source DB:  PubMed          Journal:  Khirurgiia (Mosk)        ISSN: 0023-1207


  3 in total

1.  Is it necessary to dissect the lymph nodes around an abnormal hepatic artery in D2 lymphadenectomy for gastric cancer?

Authors:  Y Huang; C Liu; J L Lin; G C Mu; Y Zeng
Journal:  Clin Transl Oncol       Date:  2012-11-10       Impact factor: 3.405

2.  The pattern of lymph node metastasis and the suitability of 7th UICC N stage in predicting prognosis of remnant gastric cancer.

Authors:  Fangxuan Li; Rupeng Zhang; Han Liang; Hui Liu; Jichuan Quan; Jingzhu Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-03       Impact factor: 4.553

3.  The application of ultrasonic harmonic scalpel in the radical surgery of gastric cancer.

Authors:  Y Huang; G C Mu; X G Qin; J L Lin; C Liu; Z B Chen; Y J Zeng
Journal:  Clin Transl Oncol       Date:  2013-03-22       Impact factor: 3.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.